Skip to main content

Table 1 Profile of NK cells derived from healthy donors and bladder cancer patients

From: Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells

  Healthy donors Bladder cancer patients
51Cr-release assay
HT-1376 80.12 ± 4.14 % 38.67 ± 8.88 %***
HT-1376 spheres 75.44 ± 6.53 % 11.74 ± 3.12 %***
UM-UC3 73.69 ± 5.40 % 41.38 ± 10.71 %**
UM-UC3 spheres 67.52 ± 7.61 % 18.19 ± 4.17 %***
NCRs
NKp30 54.68 ± 4.98 % 33.55 ± 5.09 %*
NKp44 26.35 ± 9.18 % 0.52 ± 0.20 %***
NKp46 42.93 ± 3.70 % 49.09 ± 6.09 %
NKp80 98.34 ± 0.32 % 91.36 ± 2.20 %**
 CD62L 33.40 ± 1.44 % 24.30 ± 2.57 %*
 CD57 31.08 ± 2.54 % 20.86 ± 2.14 %**
Cytokines
TNF-α 0.36 ± 0.13 % 0.23 ± 0.08 %
IFN-γ 0.23 ± 0.06 % 0.08 ± 0.03 %
TGF-β 0.14 ± 0.02 % 0.32 ± 0.15 %
IL-4 0.007 ± 0.003 % 0.42 ± 0.24 %
IL-10 0.81 ± 0.19 % 3.36 ± 1.62 %
  1. 51Cr chromium-51, NCRs natural cytotoxic receptors
  2. *P < 0.05; **P < 0.01; ***P < 0.001 healthy donors (n = 8) vs. bladder cancer patients (n = 10)